Novo Sales Down 2% Due to Lower Prices, CFO Says

Novo Sales Down 2% Due to Lower Prices, CFO Says Play

Feb. 2 (Bloomberg) -- Jesper Brandgaard, chief financial officer of Novo Nordisk A/S, talks about the company's fourth-quarter earnings and growth strategy. The world's largest insulin maker said net income climbed to 4.69 billion kroner ($830 million), up from 3.95 billion kroner a year earlier. Brandgaard speaks from Bagsvaerd, Denmark, with Mark Barton on Bloomberg Television's "The Pulse." (Source: Bloomberg)

  • On Air Now

    Taking Stock with Pimm Fox Watch Now

  • Next

    Bloomberg West

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

blog comments powered by Disqus